Evinacumab-dgnb Approval for Children with Familial Hypercholesterolemia
- Here's a breakdown of the references provided, formatted for clarity:
- Evkeez® (evinacumab-dgnb) AngPTL3 Antibody Approved in U.S.
- PT Staff.FDA approves first-in-class therapy for ultra-rare form of high cholesterol.
Here’s a breakdown of the references provided, formatted for clarity:
1. Regeneron. Evkeez® (evinacumab-dgnb) AngPTL3 Antibody Approved in U.S. for Children. Investor.regeneron.com. Published Febuary 9, 2024.Accessed october 2,2025. https://investor.regeneron.com/news-releases/news-release-details/evkeezar-evinacumab-dgnb-angptl3-antibody-approved-us-children
2. PT Staff.FDA approves first-in-class therapy for ultra-rare form of high cholesterol. Pharmacy Times. Published February 12, 2021. Accessed October 2, 2025.https://www.pharmacytimes.com/view/fda-approves-first-in-class-therapy-for-ultra-rare-form-of-high-cholesterol
3. PT Staff. FDA approves evinacumab-dgnb for young children with homozygous familial hypercholesterolemia.pharmacy Times. Published March 22, 2023. accessed October 2, 2025. https://www.pharmacytimes.com/view/fda-approves-evinacumab-dgnb-young-children-with-homozygous-familial